86239-00-1

Basic information

• Product Name: RARECHEM AL BI 0500
• Synonyms: RARECHEM AL BI 0500;3-FLUORO-4-METHYLBENZOIC ACID ETHYL ESTER;Ethyl 3-fluoro-4-Methylbenzoate
• CAS NO: 86239-00-1
• Molecular Formula: C₁₀H₁₁FO₂
• Molecular Weight: 182.19
• Mol File: 86239-00-1.mol

Chemical Properties

• Boiling Point: 240.826°C at 760 mmHg
• Flash Point: 96.653°C
• Appearance: /
• Density: 1.109g/cm³
• Vapor Pressure: 0.037mmHg at 25°C
• Refractive Index: 1.49
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: RARECHEM AL BI 0500(CAS DataBase Reference)
• NIST Chemistry Reference: RARECHEM AL BI 0500(86239-00-1)
• EPA Substance Registry System: RARECHEM AL BI 0500(86239-00-1)

Safety Data

• Hazardous Substances Data: 86239-00-1(Hazardous Substances Data)

Usage

Uses

Used in Alloy Production:
RARECHEM AL BI 0500 is used as a component in the production of high-strength alloys, contributing to their enhanced mechanical properties and performance.
Used in Magnetic Material Production:
RARECHEM AL BI 0500 is utilized in the creation of magnetic materials, taking advantage of its magnetic properties for various applications.
Used in Specialty Ceramics Production:
RARECHEM AL BI 0500 is employed in the production of specialty ceramics, where its unique properties contribute to the development of advanced ceramic materials.
Used as a Catalyst in Chemical Reactions:
RARECHEM AL BI 0500 serves as a catalyst in certain chemical reactions, facilitating and enhancing the process to achieve desired outcomes.

InChI:InChI=1/C10H11FO2/c1-3-13-10(12)8-5-4-7(2)9(11)6-8/h4-6H,3H2,1-2H3

Upstream product

• 64-17-5 ethanol 
• 350-28-7 3-fluoro-4-methyl-benzoic acid 

Downstream Products

• 86239-01-2 ethyl 4-(bromomethyl)-3-fluorobenzoate 
• 1239964-20-5 ethyl 3-chloro-5-fluoro-4-methylbenzoate 
• 1239957-32-4 3-chloro-4-(2-(5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-yl)ethyl)-5-fluorobenzenesulfonic acid 
• 1239963-70-2 tert-butyl 3-chloro-4-(2-(5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-yl)ethyl)-5-fluorophenylcarbamate 
• 1239957-31-3 3-chloro-4-(2-(5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-yl)ethyl)-5-fluorobenzoic acid 
• 1239963-69-9 ethyl 3-chloro-4-(2-(5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-yl)ethyl)-5-fluorobenzoate 
• 1239963-68-8 ethyl 3-chloro-4-(2-(5-(2-(4-chloro-3-methoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazol-2-yl)vinyl)-5-fluorobenzoate 
• 1239963-67-7 (2-chloro-4-(ethoxycarbonyl)-6-fluorobenzyl)triphenylphosphonium bromide 
• 1239964-21-6 ethyl 4-(bromomethyl)-3-chloro-5-fluorobenzoate 
• 1239964-19-2 ethyl 3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 86238-93-9 (E)-3-(4-carbethoxy-2-fluorophenyl)-2-methylpropenal 
• 86238-93-9 (Z)-3-(4-carbethoxy-2-fluorophenyl)-2-methylpropenal 
• 86238-75-7 (E)-1-(4-carbethoxy-2-fluorophenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)butadiene 
• 86238-86-0 diethyl (4-carbethoxy-2-fluorobenzyl)phosphonate 

Relevant articles and documents

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise

BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR

The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a pharmaceutically acceptable salt thereof.

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

A series of 3-substituted benzamide derivatives structurally related to STI-571 (imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), was prepared and evaluated for antiproliferative activity against the Bc

NOVEL IMIDAZOLES WITH ANTI-INFLAMMATORY ACTIVITY

Compounds of formula I wherein: one of X or Y represents N and the other represents C; R1 represents hydrogen, methyl, halogen, cyano, nitro, -CHO, -COCH3 or -COOR4; R2 represents optionally-substituted aryl or heteroaryl; R3 represents C1-8 alkyl, C1-8 haloalkyl or -NR4R6; R4 represents hydrogen, C1-8 alkyl or arylC0-8 alkyl; R6 represents hydrogen, C1-8 alkyl, arylC1-8 alkyl, -COR8 or -COOR8; R8 represents C1-8 alkyl or C1-8 haloalkyl; aryl in the above definitions represents phenyl or naphthyl; and heteroaryl in the above definitions represents pyridine, pyrazine, pyrimidine or pyridazine, which can be optionally fused to a benzene ring. These compounds are useful as cyclooxygenase-2 inhibitors.

Aromatic Retinoic Acid Analogues. 2. Synthesis and Pharmacological Activity

Aromatic analogues of (E)-1-(4-carboxyphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)butadiene (1b) and its ethyl ester (1a) were synthesized as potential chemopreventive agents for the treatment of epithelial cancer and such skin diseases as psoriasis and cystic acne.The phenyl ring of 1 was replaced by 2-fluorophenyl, 2-methoxyphenyl, thienyl, furanyl, and pyridyl groups.The 1-fluorobutadiene analogue of 1 was also synthesized.With exception for the furanyl analogue, these compounds demonstrated good activity in reversing keratinization in hamster tracheal organ culture and in inhibiting the induction of ornithine decarboxylase in mouse epidermis by a tumor promoter.